Loxicom Oral Suspension Cats
Loxicom Oral for cats is an oral suspension for cats contains 0.5mg of meloxicam. It can be used to alleviate mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery as well as in acute and chronic musculo-skeletal disorders.
Target Species: Cats
-
Active Ingredient
Each ml contains: Active Substance: Meloxicam 0.5 mg Excipient: Sodium benzoate 1.5 mg
-
Pharmaceutical Form
Pale yellow oral suspension.
-
Indications
Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in cats.
-
Dosage
Oral use. To be administered with food or directly into the mouth. Shake well before use. Dosage: Post-operative pain and inflammation following surgical procedures: After initial treatment with Loxicom 5 mg/ml Solution for Injection for Dogs and Cats continue treatment 24 hours later with Loxicom 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days. Acute musculo-skeletal disorders: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain and inflammation persist. Chronic musculo-skeletal disorders: Initial treatment is a single dose of 0.1 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg bodyweight. A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent. Dosing Procedure: The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required. For initiation of the treatment of acute musculo-skeletal disorders on the first day, 4 times the maintenance volume will be required. Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded. The suspension should be given using the Loxicom measuring syringe provided in the package. Avoid introduction of contamination during use.
Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region or visit the local government agency website for the most up to date information. Please see our terms and conditions for further information.
Prefer to speak directly to a member of our team?
Norbrook MENA
All enquiries for the MENA team are manged by the Norbrook Head Office in Northern Ireland
We are open Mon - Fri 9:00am - 5:00pm